CompletedPhase 2NCT00025233
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Studying Squamous cell carcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Bradley Monk, MDGynecologic Oncology Group
- Intervention
- bevacizumab(biological)
- Enrollment
- 50 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2002 – 2009
Study locations (1)
- Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Collaborators
Gynecologic Oncology Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00025233 on ClinicalTrials.gov